CALGB 80702: A Phase III Trial of 6 versus 12 Treatments of Adjuvant Folfox Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer

Study Status

Open to Enrollment

Study Description

This is a study for patients with colon cancer that has been surgically removed but has spread to lymph nodes. 

The purpose of this study is to evaluate the efficacy of the oral drug celecoxib when given in combination with FOLFOX chemotherapy in decreasing colon cancer recurrence. The study will also look at whether receiving FOLFOX chemotherapy for 6 treatments (12 weeks) is as effective as 12 treatments (24 weeks) in preventing recurrence of colon cancer.

FOLFOX is approved by the FDA and is standard treatment used to prevent colon cancer from recurring. Celecoxib is approved by the FDA to treat arthritis and to help prevent colon polyps. The addition of celecoxib to FOLFOX therapy is experimental.

Patients will be randomized to one of four treatment groups: g

  • Group 1: FOLFOX for 12 treatments (24 weeks) + placebo (a substance containing no medicine that looks like celecoxib) by mouth every day for 3 years
  • Group 2: FOLFOX for 12 treatments + celecoxib by mouth every day for 3 years
  • Group 3: FOLFOX for 6 treatments (12 weeks) + placebo by mouth every day for 3 years
  • Group 4: FOLFOX for 6 treatments + celecoxib by mouth every day for 3 years

Patients will be treated with FOLFOX chemotherapy for up to 6 treatments (12 weeks) or 12 treatments (24 weeks), depending on which treatment arm they are assigned to, and will take celecoxib or placebo for up to 3 years.

Disease Status and/or Stage

Resected Stage III Colon Cancer

Sponsor

CALGB

Key Eligibility

  • Colon cancer
  • Tumor must be completely resected (removed)
  • Treatment must begin between 21 and 56 days after surgical resection of tumor
  • Detailed eligibility reviewed when you contact the study team

Principal Investigator

Allyson Ocean, MD

Contact

Protocol ID

CALGB 80702


Healthy Volunteers

healthy_volunteers.jpg

As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please e-mail:
Erica Bersin
Manager, Subject Recruitment & Communications
(646) 962-8232
erb3001@med.cornell.edu
http://jcto.weill.cornell.edu

Top of page